…abstract presenting early clinical results from the Phase 1, first-in-human investigator-initiated trial (IIT) of C-CAR168 in Chinese patients with refractory autoimmune disease The post AbelZeta Announces Upcoming Oral Presentations at LUPUS 2025 appeared first on AbelZeta Pharma .